Scancell ^Companies

Scancell is a clinical stage biopharmaceutical company focused on developing innovative immunotherapies for cancer. Their main goal is to stimulate the body's own immune system to fight against cancer cells. They are developing therapeutic vaccines based on their ImmunoBody® and Moditope™ technology platforms. Their first cancer vaccine, SCIB1, is currently in Phase 1/2 clinical trials for the treatment of melanoma. Preliminary evidence from the study has shown that SCIB1 produced an immune response that may be associated with clinical benefit in patients with malignant melanoma.